Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.
about
New advances in the treatment of generalized lipodystrophy: role of metreleptinLeptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individualsLeptin applications in 2015: what have we learned about leptin and obesity?Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic StrategiesLeptin revisited: its mechanism of action and potential for treating diabetes.Obesity as an effect modifier of the association between leptin and diabetic kidney disease.Dietary combination of sucrose and linoleic acid causes skeletal muscle metabolic abnormalities in Zucker fatty rats through specific modification of fatty acid composition.Does leptin predict incident hypertension in older adults?Metreleptin: first global approval.Current status of therapy in nonalcoholic Fatty liver disease.Lipodystrophy: pathophysiology and advances in treatmentLeptin administration to overweight and obese subjects for 6 months increases free leptin concentrations but does not alter circulating hormones of the thyroid and IGF axes during weight loss induced by a mild hypocaloric diet.Therapeutic impact of leptin on diabetes, diabetic complications, and longevity in insulin-deficient diabetic miceLeptin replacement therapy for the treatment of non-HAART associated lipodystrophy syndromes: a meta-analysis into the effects of leptin on metabolic and hepatic endpoints.Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experienceAssociation of serum leptin levels with progression of diabetic kidney disease in patients with type 2 diabetes.Repositioning leptin as a therapy for Alzheimer's diseasePartial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes.Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety.FOSL2 promotes leptin gene expression in human and mouse adipocytes.Seipin: from human disease to molecular mechanismLeptin in relation to the lipodystrophy-associated metabolic syndromeFunctional magnetic resonance imaging analysis of food-related brain activity in patients with lipodystrophy undergoing leptin replacement therapy.Decrease in hepatic very-low-density lipoprotein-triglyceride secretion after weight loss is inversely associated with changes in circulating leptin.Leptin activates hepatic 5'-AMP-activated protein kinase through sympathetic nervous system and α1-adrenergic receptor: a potential mechanism for improvement of fatty liver in lipodystrophy by leptinCentral leptin insufficiency syndrome: an interactive etiology for obesity, metabolic and neural diseases and for designing new therapeutic interventions.Lymphoma in acquired generalized lipodystrophy.A case for new therapy for diabetes, is it leptin?Leptin therapy, insulin sensitivity, and glucose homeostasis.Benefits of leptin therapy in HIV patients.Berardinelli-Seip syndrome: highlight of treatment challengeLeptin may enhance hepatic insulin sensitivity in children and women born small for gestational age.Leptin therapy for partial lipodystrophy linked to a PPAR-gamma mutation.Intracellular lipid accumulation in liver and muscle and the insulin resistance syndrome.Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophyChanges in insulin sensitivity during leptin replacement therapy in leptin-deficient patients.Selective leptin resistance revisited.Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment.The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia.
P2860
Q26781946-2D4E024D-8F29-4F3E-BFBF-324CE44BC6FAQ26859118-4B5ED64A-B47D-4BA0-8236-01DA356F0CF9Q28087233-9E775CFE-1CEF-4A14-A73C-86B713FDDF45Q28088325-F3191079-FC4E-4470-B46C-D4A1C181DF75Q33602487-D8422E90-A66A-468C-BFA6-6A56E600850FQ33622272-8559D568-DD51-4131-AEC9-7DC889AFC3B8Q33832051-7A01BF72-349B-44BA-BDDB-20AD6DE488A2Q33936634-2EBF350B-C0C1-4305-AFD0-B0D74FA7A4C4Q34348966-99E1FFA4-7D2D-4B2D-A914-B4FF9448B863Q34408961-7A8B9CC5-0312-4605-BE66-907D5730150BQ35148915-B331358A-72F9-47D7-AF76-CC5E5EF5F2FAQ35174427-7B3880B0-4153-4996-AF85-C6DB692E0A78Q35180084-4D82CBD7-59C8-4829-98F3-1D08A31468B2Q35480563-254CB2B4-DDD5-4FE8-83C8-BC201A760659Q35547148-3DAEBFC8-34A6-420C-880B-FC8E5FB531F2Q35563693-BB7B5E4E-6B64-4472-826D-F1BBCD6AD09AQ35569809-58700045-41D8-42B1-94B3-8B2F630F98ECQ35578335-2D15D34D-A4EC-466E-8FD2-4067755144E4Q35796963-143501E1-4C30-48E1-B38C-17DC797439AFQ35869668-05497879-00EA-45C9-B158-AAC044DFC00FQ35878661-47B63334-5846-4BD4-8875-100A88E39777Q35958418-70D91907-241D-4480-9321-E0FB04CB156EQ36049195-4862777A-E541-49F5-9C3E-CE0EFBDFB13BQ36293562-AE98A455-5881-4D66-8AC1-043B4F1FECA5Q36367336-E3F00648-B3A3-41F2-B121-7E16B25626F6Q36418845-A8DB06F0-8C20-4549-A129-3EEE36675761Q36464854-63438BE2-FC81-4643-BDDE-24E828267A81Q36584738-67676024-7E5F-4FE9-AAFC-90B3474BE433Q36700857-BAD59DA4-4294-45CB-AEE7-E343E7F8BF99Q36700877-A95D9714-C200-4DC9-910B-52CBA9FF4D8DQ36700922-3359DBDF-19F5-4FEF-B4E0-16545BE491B6Q36704607-94F7DD94-3DDA-4287-AF90-413AF68CD441Q36924525-47F4D344-BF47-42CA-B366-2578B98B734BQ36962898-3971D8F7-5E73-440B-8A75-E1AAD7C0D62EQ37052532-B75889BC-4482-48C8-BAC9-98E0BA2F64E2Q37062692-D10EB164-7F35-40F1-AD3A-55984971E554Q37120226-8EF9CBE0-0BB8-4DAE-BD06-CC06D654ACEAQ37147129-11DCFDEF-770B-4DB3-9FA5-D805C61CC22FQ37149405-BBB27343-2A34-4CDD-B6F8-42D7F6C9AC7FQ37193194-28AD1EE5-E1E9-41F5-89CB-054475F80FDE
P2860
Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Efficacy and safety of leptin- ...... ith generalized lipodystrophy.
@en
Efficacy and safety of leptin- ...... ith generalized lipodystrophy.
@nl
type
label
Efficacy and safety of leptin- ...... ith generalized lipodystrophy.
@en
Efficacy and safety of leptin- ...... ith generalized lipodystrophy.
@nl
prefLabel
Efficacy and safety of leptin- ...... ith generalized lipodystrophy.
@en
Efficacy and safety of leptin- ...... ith generalized lipodystrophy.
@nl
P2093
P356
P1476
Efficacy and safety of leptin- ...... with generalized lipodystrophy
@en
P2093
Alex M DePaoli
Fumiko Miyanaga
Hideki Chusho
Hiroaki Masuzaki
Kazuwa Nakao
Ken Ebihara
Kiminori Hosoda
Masakazu Hirata
Masanori Fukushima
Nozomi Kobayashi
P304
P356
10.1210/JC.2006-1546
P407
P577
2006-11-21T00:00:00Z